Activating mutations in the RAS/RAF/MEK/ERK signaling pathway downstream of EGFR generally confer resistance to anti-EGFR therapies; however, recent developments have led to new approaches for therapeutically targeting CRC with RAS or BRAF mutations [29]. This evidence concerns the gene BRAF and colorectal carcinoma.